NCT03320707View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

August 27, 2019

Study Completion Date

August 27, 2019

Conditions
Healthy
Interventions
DRUG

Daratumumab

Single SC dose of daratumumab will be administered in each of 8 dose cohorts.

DRUG

Placebo

Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.

DRUG

rHuPH20

Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03320707 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants | Biotech Hunter | Biotech Hunter